Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1992-05-13
1994-12-20
Witshyn, Michael G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530350, 530384, A61K 3702
Patent
active
053746171
ABSTRACT:
It has been discovered that it is possible to administer truncated tissue factor (not having the transmembrane region) (tTF) in combination with factor VIIa (F VIIa) to treat bleeding disorders such as those resulting from hemophilia or cirrhosis of the liver. The tTF is administered to produce up to 10 .mu.g tTF/ml of plasma. The F VIIa is administered to produce levels of between 40 ng VIIa/ml and 4 .mu.g F VIIa/ml of plasma. The effective dosages of both tTF and VIIa are significantly and surprisingly less than the administration of either alone to stop bleeding. Examples demonstrate safety and efficacy in normal and hemophilic dogs.
REFERENCES:
patent: 4479938 (1984-10-01), Thomas
patent: 5180583 (1993-01-01), Hedner
de Sousa, et al., "Factor VII Hyperactivity in Acute Myocardial Thrombosis, A Relation to the Coagulation Activation" Thrombosis Research vol. 51, No. 2, pp. 165-173 (1988).
Poggio, et al., "Factor VII Clotting Assay: Influence of Different Thromboplastins and Factor VII-Deficient Plasmas", Thrombosis and Haemostasis vol. 65, No. 2, pp. 160-164 (1991).
Morrissey, et al., "Molecular Cloning of the cDNA for Tissue Factor, the Cellular Receptor for the Initiation of the Coagulation Protease Cascade", Cell vol. 50, pp. 129-135 (Jul. 3, 1987).
Spicer, et al., "Isolation of cDNA clones coding for human tissue factor: Primary structure of the protein and cDNA", Proceedings of the National Academy of Sciences U.S.A. vol. 84, pp. 514j8-5152 (Aug. 1987).
Scarpati, et al., "Human Tissue Factor: cDNA Sequence and Chromosome Localization of the Gene", Biochemistry vol. 26, No. 17, pp. 5234-5238 (1987).
Fischer, et al., "Cloning and Expression of Human Tissue Factor cDNA", Thrombosis Research vol. 48, No. 1, pp. 89-99 (1987).
Paborsky, et al., "Purification of Recombinant Human Tissue Factor", Biochemistry vol. 28, No. 20, pp. 8072-8077 (1989).
Paborsky, et al., "Post-Translational Modifications of Recombinant Human Tissue Factor", Thrombosis Research vol. 60, No. 5, pp. 367-376 (1990).
Ruf, et al., "The Isolated Extracellular Domain of Tissue Factor is Functional on Phospholipid Surfaces", Thrombosis and Haemostasis vol. 62, p. 347 (1989).
Ruf, et al., "Phospholipid-independent and dependent Interactions Required for Tissue Receptor and Cofactor Function", Journal of Biological Chemistry vol. 266, No. 4, pp. 2158-2166 (Feb. 5, 1991).
Hoffman, et al., "Factor VII activity state in coronary artery disease", Journal of Laboratory Clinical Medicine, vol. 111, No. 4, pp. 475-481 (Apr. 1988).
Gordon, et al., "Augmented Hageman factor and prolactin titers, enhanced cold activation of factor VII, and spontaneous shortening of prothrombin time in survivors of mycardial infarction", Journal of Laboratory Clinical Medicine vol. 109, No. 3, pp. 409-413 (Apr. 1987).
Mitropoulos, K. A., "Hypercoagulability and Factor VII Hypertriglyceridemia" Seminars in Thrombosis and Hemostasis vol. 14, No. 3, pp. 246-252 (1988).
Scarabin, et al., "Is Factor VII Activation in Pregnant Women Relevant to Fetal Growth Retardation?", Thrombosis Research vol. 45, No. 6, pp. 845-850 (1987).
Paborsky et al J. Biol. Chem. 266: 21911-16 (1991).
Hapak, et al., "The location of the active site of Factor VIIa above the membrane surface is altered by either full-length or truncated tissue factor," FASEB Journal 6:A330, Abstract No. 1900 (1992).
Comp Philip C.
Morrissey James H.
Koh Choon P.
Oklahoma Medical Research Foundation
Witshyn Michael G.
LandOfFree
Treatment of bleeding with modified tissue factor in combination does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of bleeding with modified tissue factor in combination, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of bleeding with modified tissue factor in combination will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2386269